Immunic (NASDAQ:IMUX) Coverage Initiated at HC Wainwright

HC Wainwright started coverage on shares of Immunic (NASDAQ:IMUX) in a report released on Monday morning, Marketbeat reports. The brokerage issued a buy rating and a $10.00 target price on the stock.

Other equities research analysts have also issued research reports about the stock. B. Riley began coverage on shares of Immunic in a research note on Tuesday, August 27th. They set a “buy” rating and a $6.00 target price for the company. EF Hutton Acquisition Co. I raised shares of Immunic to a “strong-buy” rating in a research note on Monday, September 16th. StockNews.com lowered shares of Immunic from a “hold” rating to a “sell” rating in a research note on Monday, November 11th. Leerink Partners reissued an “outperform” rating and set a $5.00 target price on shares of Immunic in a research note on Monday, September 9th. Finally, Leerink Partnrs upgraded shares of Immunic to a “strong-buy” rating in a report on Monday, September 9th. One investment analyst has rated the stock with a sell rating, five have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $11.80.

Immunic Stock Up 7.3 %

Shares of NASDAQ:IMUX opened at $1.18 on Monday. The firm has a fifty day moving average of $1.39 and a two-hundred day moving average of $1.34. The firm has a market capitalization of $106.29 million, a P/E ratio of -0.96 and a beta of 1.88. Immunic has a 12-month low of $0.97 and a 12-month high of $2.11.

Insider Activity

In other news, Director Richard Alan Rudick bought 87,300 shares of the company’s stock in a transaction that occurred on Tuesday, November 12th. The shares were purchased at an average price of $1.15 per share, for a total transaction of $100,395.00. Following the acquisition, the director now directly owns 87,300 shares of the company’s stock, valued at $100,395. The trade was a ? increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 3.00% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of IMUX. Vanguard Group Inc. raised its holdings in Immunic by 100.7% in the 1st quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company’s stock worth $4,480,000 after acquiring an additional 1,703,047 shares during the period. Janus Henderson Group PLC bought a new position in Immunic in the 1st quarter worth $9,266,000. Ikarian Capital LLC raised its holdings in Immunic by 258.3% in the 1st quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company’s stock worth $2,128,000 after acquiring an additional 1,162,378 shares during the period. Virtu Financial LLC bought a new position in shares of Immunic during the 1st quarter worth about $25,000. Finally, Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Immunic by 70.8% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock worth $169,000 after purchasing an additional 42,383 shares during the period. Institutional investors own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.